Merck & Company Inc (MRK)vsTango Therapeutics Inc (TNGX)
MRK
Merck & Company Inc
$109.18
+2.73%
HEALTHCARE · Cap: $274.03B
TNGX
Tango Therapeutics Inc
$20.98
-2.96%
HEALTHCARE · Cap: $3.18B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 104111% more annual revenue ($65.01B vs $62.38M). MRK leads profitability with a 28.1% profit margin vs -162.9%. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
TNGX
Avoid20
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-16.2%
Fair Value
$96.56
Current Price
$109.18
$12.62 premium
Margin of Safety
+21.7%
Fair Value
$16.11
Current Price
$20.98
$4.87 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
No standout strengths identified
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Trading at 8.2x book value
0.0% earnings growth
ROE of -37.2% — below average capital efficiency
Revenue declined 100.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : TNGX
TNGX has a balanced fundamental profile.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : TNGX
The primary concerns for TNGX are Price/Book, EPS Growth, Return on Equity.
Key Dynamics to Monitor
MRK profiles as a value stock while TNGX is a turnaround play — different risk/reward profiles.
TNGX carries more volatility with a beta of 1.31 — expect wider price swings.
MRK is growing revenue faster at 5.0% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 20/100), backed by strong 28.1% margins. TNGX offers better value entry with a 21.7% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Tango Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Tango Therapeutics Inc. is a clinical-stage biotechnology firm focused on revolutionizing cancer treatment through targeted therapies based on the principle of synthetic lethality. With a robust and diverse pipeline of innovative drug candidates, the company is poised to make significant strides in precision oncology. Tango is committed to enhancing its research capabilities through strategic partnerships with esteemed academic institutions, further solidifying its role as a leader in advancing treatment paradigms in oncology. Through its visionary approach, Tango aims to address critical unmet needs in cancer care and significantly improve patient outcomes.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?